SCHEMBL3367903

SCHEMBL3367903

CSc1cc(-c2ccc(Oc3ccccc3)cc2)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
LTA4H P09960 1/20 0.43
SCN4A P35499 1/20 0.43
XDH P47989 1/20 0.43
ALPL P05186 2/20 0.41
CA9 Q16790 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
KMT2A Q03164 2/20 0.41
RELA Q04206 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374927 0.85 L3MBTL1 (0.58) L3MBTL1RAB9APOLBADORA3LMNA
SCHEMBL31371340 0.83 RAB9A (0.63) L3MBTL1RAB9ANPC1MAPTMAPK1
SCHEMBL31371407 0.77 ALPL (0.51) L3MBTL1RAB9ANPC1MAPTALPL
SCHEMBL6441397 0.76 RAB9A (0.73) RAB9ANPC1MAPTMAPK1LTA4H
SCHEMBL2867210 0.76 AXL (0.53) L3MBTL1RAB9ANPC1MAPTMAPK1
SCHEMBL31371362 0.76 TRPM8 (0.53) L3MBTL1RAB9ANPC1MAPTMAPK1
SCHEMBL19533530 0.74 ALPL (0.59) L3MBTL1RAB9ANPC1MAPTALPL
SCHEMBL12473765 0.74 ALPL (0.52) L3MBTL1RAB9ANPC1MAPTMAPK1
SCHEMBL16128887 0.73 ALPL (0.55) L3MBTL1RAB9ANPC1MAPTALPL
SCHEMBL2561357 0.73 TP53 (0.73) ALPLCA9ADORA3HPGDSMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266960-B1 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants EURO CELTIQUE SA (LU) 2014-01-22 EP disclosed
EP-2266960-A2 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants EURO-CELTIQUE S.A. (LU) 2010-12-29 EP disclosed
EP-1173169-B1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO CELTIQUE SA (LU) 2010-05-12 EP disclosed
EP-1173169-A4 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO CELTIQUE SA (LU) 2007-04-04 EP disclosed
US-6737418-B2 CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS EURO-CELTIQUE S.A. (LU) 2004-05-18 US disclosed
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof EURO-CELTIQUE S.A. 2003-04-10 US disclosed
US-6414011-B1 CENTRAL NERVOUS SYSTEM DISORDERS EURO-CELTIQUE S.A. (LU) 2002-07-02 US disclosed
CN-1353605-A Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof EURO CELTIQUE SA (LU) 2002-06-12 CN disclosed
EP-1173169-A1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF Euro-Celtique S.A. (LU) 2002-01-23 EP disclosed
WO-2000057877-A1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof GRIK5, GRIN3A, GRIK3 L3MBTL1 185/4885RAB9A 3883/4885NPC1 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.